Report Detail

Pharma & Healthcare Global Pulmonary Arterial Hypertension (PAH) Drugs Market Insights, Forecast to 2025

  • RnM2410103
  • |
  • 21 April, 2019
  • |
  • Global
  • |
  • 122 Pages
  • |
  • QYResearch
  • |
  • Pharma & Healthcare

The global Pulmonary Arterial Hypertension (PAH) Drugs market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to define, segment, and project the size of the Pulmonary Arterial Hypertension (PAH) Drugs market based on company, product type, end user and key regions.

This report studies the global market size of Pulmonary Arterial Hypertension (PAH) Drugs in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Pulmonary Arterial Hypertension (PAH) Drugs in these regions.
This research report categorizes the global Pulmonary Arterial Hypertension (PAH) Drugs market by top players/brands, region, type and end user. This report also studies the global Pulmonary Arterial Hypertension (PAH) Drugs market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Pfizer
Glaxosmithkline
Novartis
United Therapeutics
AstraZeneca
Merck
Bayer Healthcare
Actelion Pharmaceuticals
Daiichi Sankyo
Northern Therapeutics
Aires Pharmaceuticals
Arena Pharmaceuticals
Berlin Cures
Eiger BioPharmaceuticals
Reata Pharmaceuticals

Market size by Product
Inhalation
Injectables
Oral Administration
Market size by End User
Hospitals
Clinics
Other

Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa

The study objectives of this report are:
To study and analyze the global Pulmonary Arterial Hypertension (PAH) Drugs market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Pulmonary Arterial Hypertension (PAH) Drugs market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Pulmonary Arterial Hypertension (PAH) Drugs companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Pulmonary Arterial Hypertension (PAH) Drugs submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

In this study, the years considered to estimate the market size of Pulmonary Arterial Hypertension (PAH) Drugs are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025

This report includes the estimation of market size for value (million US$) and volume (K Pcs). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Pulmonary Arterial Hypertension (PAH) Drugs market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.


Table of Contents

    1 Study Coverage

    • 1.1 Pulmonary Arterial Hypertension (PAH) Drugs Product
    • 1.2 Market Segments
    • 1.3 Key Manufacturers Covered
    • 1.4 Market by Type
      • 1.4.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Market Size Growth Rate by Product
      • 1.4.2 Inhalation
      • 1.4.3 Injectables
      • 1.4.4 Oral Administration
    • 1.5 Market by End User
      • 1.5.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Market Size Growth Rate by End User
      • 1.5.2 Hospitals
      • 1.5.3 Clinics
      • 1.5.4 Other
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Executive Summary

    • 2.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Market Size
      • 2.1.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue 2014-2025
      • 2.1.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales 2014-2025
    • 2.2 Pulmonary Arterial Hypertension (PAH) Drugs Growth Rate by Regions
      • 2.2.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Regions
      • 2.2.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Regions

    3 Breakdown Data by Manufacturers

    • 3.1 Pulmonary Arterial Hypertension (PAH) Drugs Sales by Manufacturers
      • 3.1.1 Pulmonary Arterial Hypertension (PAH) Drugs Sales by Manufacturers
      • 3.1.2 Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Manufacturers
      • 3.1.3 Global Pulmonary Arterial Hypertension (PAH) Drugs Market Concentration Ratio (CR5 and HHI)
    • 3.2 Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Manufacturers
      • 3.2.1 Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Manufacturers (2014-2019)
      • 3.2.2 Pulmonary Arterial Hypertension (PAH) Drugs Revenue Share by Manufacturers (2014-2019)
    • 3.3 Pulmonary Arterial Hypertension (PAH) Drugs Price by Manufacturers
    • 3.4 Pulmonary Arterial Hypertension (PAH) Drugs Manufacturing Base Distribution, Product Types
      • 3.4.1 Pulmonary Arterial Hypertension (PAH) Drugs Manufacturers Manufacturing Base Distribution, Headquarters
      • 3.4.2 Manufacturers Pulmonary Arterial Hypertension (PAH) Drugs Product Type
      • 3.4.3 Date of International Manufacturers Enter into Pulmonary Arterial Hypertension (PAH) Drugs Market
    • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Product

    • 4.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Product
    • 4.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Product
    • 4.3 Pulmonary Arterial Hypertension (PAH) Drugs Price by Product

    5 Breakdown Data by End User

    • 5.1 Overview
    • 5.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Breakdown Data by End User

    6 North America

    • 6.1 North America Pulmonary Arterial Hypertension (PAH) Drugs by Countries
      • 6.1.1 North America Pulmonary Arterial Hypertension (PAH) Drugs Sales by Countries
      • 6.1.2 North America Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Countries
      • 6.1.3 United States
      • 6.1.4 Canada
      • 6.1.5 Mexico
    • 6.2 North America Pulmonary Arterial Hypertension (PAH) Drugs by Product
    • 6.3 North America Pulmonary Arterial Hypertension (PAH) Drugs by End User

    7 Europe

    • 7.1 Europe Pulmonary Arterial Hypertension (PAH) Drugs by Countries
      • 7.1.1 Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales by Countries
      • 7.1.2 Europe Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Countries
      • 7.1.3 Germany
      • 7.1.4 France
      • 7.1.5 UK
      • 7.1.6 Italy
      • 7.1.7 Russia
    • 7.2 Europe Pulmonary Arterial Hypertension (PAH) Drugs by Product
    • 7.3 Europe Pulmonary Arterial Hypertension (PAH) Drugs by End User

    8 Asia Pacific

    • 8.1 Asia Pacific Pulmonary Arterial Hypertension (PAH) Drugs by Countries
      • 8.1.1 Asia Pacific Pulmonary Arterial Hypertension (PAH) Drugs Sales by Countries
      • 8.1.2 Asia Pacific Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Countries
      • 8.1.3 China
      • 8.1.4 Japan
      • 8.1.5 Korea
      • 8.1.6 India
      • 8.1.7 Australia
      • 8.1.8 Indonesia
      • 8.1.9 Malaysia
      • 8.1.10 Philippines
      • 8.1.11 Thailand
      • 8.1.12 Vietnam
      • 8.1.13 Singapore
    • 8.2 Asia Pacific Pulmonary Arterial Hypertension (PAH) Drugs by Product
    • 8.3 Asia Pacific Pulmonary Arterial Hypertension (PAH) Drugs by End User

    9 Central & South America

    • 9.1 Central & South America Pulmonary Arterial Hypertension (PAH) Drugs by Countries
      • 9.1.1 Central & South America Pulmonary Arterial Hypertension (PAH) Drugs Sales by Countries
      • 9.1.2 Central & South America Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Countries
      • 9.1.3 Brazil
    • 9.2 Central & South America Pulmonary Arterial Hypertension (PAH) Drugs by Product
    • 9.3 Central & South America Pulmonary Arterial Hypertension (PAH) Drugs by End User

    10 Middle East and Africa

    • 10.1 Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs by Countries
      • 10.1.1 Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales by Countries
      • 10.1.2 Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Countries
      • 10.1.3 GCC Countries
      • 10.1.4 Turkey
      • 10.1.5 Egypt
      • 10.1.6 South Africa
    • 10.2 Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs by Product
    • 10.3 Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs by End User

    11 Company Profiles

    • 11.1 Pfizer
      • 11.1.1 Pfizer Company Details
      • 11.1.2 Company Business Overview
      • 11.1.3 Pfizer Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.1.4 Pfizer Pulmonary Arterial Hypertension (PAH) Drugs Products Offered
      • 11.1.5 Pfizer Recent Development
    • 11.2 Glaxosmithkline
      • 11.2.1 Glaxosmithkline Company Details
      • 11.2.2 Company Business Overview
      • 11.2.3 Glaxosmithkline Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.2.4 Glaxosmithkline Pulmonary Arterial Hypertension (PAH) Drugs Products Offered
      • 11.2.5 Glaxosmithkline Recent Development
    • 11.3 Novartis
      • 11.3.1 Novartis Company Details
      • 11.3.2 Company Business Overview
      • 11.3.3 Novartis Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.3.4 Novartis Pulmonary Arterial Hypertension (PAH) Drugs Products Offered
      • 11.3.5 Novartis Recent Development
    • 11.4 United Therapeutics
      • 11.4.1 United Therapeutics Company Details
      • 11.4.2 Company Business Overview
      • 11.4.3 United Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.4.4 United Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Products Offered
      • 11.4.5 United Therapeutics Recent Development
    • 11.5 AstraZeneca
      • 11.5.1 AstraZeneca Company Details
      • 11.5.2 Company Business Overview
      • 11.5.3 AstraZeneca Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.5.4 AstraZeneca Pulmonary Arterial Hypertension (PAH) Drugs Products Offered
      • 11.5.5 AstraZeneca Recent Development
    • 11.6 Merck
      • 11.6.1 Merck Company Details
      • 11.6.2 Company Business Overview
      • 11.6.3 Merck Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.6.4 Merck Pulmonary Arterial Hypertension (PAH) Drugs Products Offered
      • 11.6.5 Merck Recent Development
    • 11.7 Bayer Healthcare
      • 11.7.1 Bayer Healthcare Company Details
      • 11.7.2 Company Business Overview
      • 11.7.3 Bayer Healthcare Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.7.4 Bayer Healthcare Pulmonary Arterial Hypertension (PAH) Drugs Products Offered
      • 11.7.5 Bayer Healthcare Recent Development
    • 11.8 Actelion Pharmaceuticals
      • 11.8.1 Actelion Pharmaceuticals Company Details
      • 11.8.2 Company Business Overview
      • 11.8.3 Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.8.4 Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Products Offered
      • 11.8.5 Actelion Pharmaceuticals Recent Development
    • 11.9 Daiichi Sankyo
      • 11.9.1 Daiichi Sankyo Company Details
      • 11.9.2 Company Business Overview
      • 11.9.3 Daiichi Sankyo Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.9.4 Daiichi Sankyo Pulmonary Arterial Hypertension (PAH) Drugs Products Offered
      • 11.9.5 Daiichi Sankyo Recent Development
    • 11.10 Northern Therapeutics
      • 11.10.1 Northern Therapeutics Company Details
      • 11.10.2 Company Business Overview
      • 11.10.3 Northern Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.10.4 Northern Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Products Offered
      • 11.10.5 Northern Therapeutics Recent Development
    • 11.11 Aires Pharmaceuticals
    • 11.12 Arena Pharmaceuticals
    • 11.13 Berlin Cures
    • 11.14 Eiger BioPharmaceuticals
    • 11.15 Reata Pharmaceuticals

    12 Future Forecast

    • 12.1 Pulmonary Arterial Hypertension (PAH) Drugs Market Forecast by Regions
      • 12.1.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Forecast by Regions 2019-2025
      • 12.1.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Forecast by Regions 2019-2025
    • 12.2 Pulmonary Arterial Hypertension (PAH) Drugs Market Forecast by Product
      • 12.2.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Forecast by Product 2019-2025
      • 12.2.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Forecast by Product 2019-2025
    • 12.3 Pulmonary Arterial Hypertension (PAH) Drugs Market Forecast by End User
    • 12.4 North America Pulmonary Arterial Hypertension (PAH) Drugs Forecast
    • 12.5 Europe Pulmonary Arterial Hypertension (PAH) Drugs Forecast
    • 12.6 Asia Pacific Pulmonary Arterial Hypertension (PAH) Drugs Forecast
    • 12.7 Central & South America Pulmonary Arterial Hypertension (PAH) Drugs Forecast
    • 12.8 Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Forecast

    13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

    • 13.1 Market Opportunities and Drivers
    • 13.2 Market Challenges
    • 13.3 Market Risks/Restraints
    • 13.4 Macroscopic Indicators

    14 Value Chain and Sales Channels Analysis

    • 14.1 Value Chain Analysis
    • 14.2 Pulmonary Arterial Hypertension (PAH) Drugs Customers
    • 14.3 Sales Channels Analysis
      • 14.3.1 Sales Channels
      • 14.3.2 Distributors

    15 Research Findings and Conclusion

      16 Appendix

      • 16.1 Research Methodology
        • 16.1.1 Methodology/Research Approach
        • 16.1.2 Data Source
      • 16.2 Author Details

      Summary:
      Get latest Market Research Reports on Pulmonary Arterial Hypertension (PAH) Drugs . Industry analysis & Market Report on Pulmonary Arterial Hypertension (PAH) Drugs is a syndicated market report, published as Global Pulmonary Arterial Hypertension (PAH) Drugs Market Insights, Forecast to 2025. It is complete Research Study and Industry Analysis of Pulmonary Arterial Hypertension (PAH) Drugs market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

      Last updated on

      REPORT YOU MIGHT BE INTERESTED

      Purchase this Report

      $3,900.00
      $5,850.00
      $7,800.00
      3,088.80
      4,633.20
      6,177.60
      3,603.60
      5,405.40
      7,207.20
      590,031.00
      885,046.50
      1,180,062.00
      325,143.00
      487,714.50
      650,286.00
      Credit card Logo

      Related Reports


      Reason to Buy

      Request for Sample of this report